

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*

無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

INSIDE INFORMATION PROPOSED DELISTING OF STA

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) hereby announces that at a meeting of the Board held on March 10, 2019, the Company proposed to seek delisting of Shanghai SynTheAll Pharmaceutical Co., Ltd.* (上海合全藥業股份有限公司) (“**STA**”), a subsidiary of the Company, from the National Equities Exchange and Quotations (全國中小企業股份轉讓系統) (“**NEEQ**”) (the “**Proposed Delisting**”). The Board believes that the Proposed Delisting would allow STA to focus on long-term development strategy and enhance operational efficiency, and save unnecessary administrative and other listing-related costs and expenses.

STA is principally engaged in contract development and manufacturing services in relation to small molecular drugs. The trading of shares in STA on NEEQ shall be suspended from March 11, 2019. As of the date of this announcement, STA is indirectly owned as to 85.88% by the Company.

As at the date of this announcement, no material terms concerning the Proposed Delisting have been agreed and the Company has not entered into any definitive agreement in relation to the Proposed Delisting. The Company may or may not acquire any of the remaining minority interests of STA. Such acquisition, if any, might constitute notifiable and/or connected transactions pursuant to the Listing Rules. The Board will make further announcement as and when necessary in compliance with the Listing Rules and applicable laws.

The Proposed Delisting may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
WuXi AppTec Co., Ltd.
Dr. Ge Li
Chairman

Hong Kong, March 10, 2019

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

** For identification purpose only*